Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated:  9/25/2017
Aspen Clinical Research, LLC
mi
from
Orem, UT
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Aspen Clinical Research, LLC
mi
from
Orem, UT
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated:  9/25/2017
Alliance Research Group
mi
from
Richmond, VA
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Alliance Research Group
mi
from
Richmond, VA
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated:  9/25/2017
Brighton Research Group, LLC
mi
from
Virginia Beach, VA
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Brighton Research Group, LLC
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated:  9/25/2017
Eastside Therapeutic Resource
mi
from
Kirkland, WA
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Eastside Therapeutic Resource
mi
from
Kirkland, WA
Click here to add this to my saved trials
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease Using a Safe, Low Dose Aspirin Challenge
Status: Enrolling
Updated:  9/26/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease Using a Safe, Low Dose Aspirin Challenge
Status: Enrolling
Updated: 9/26/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Birmingham, AL
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Centennial, CO
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Centennial, CO
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Miami, FL
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Chicago, IL
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Chicago, IL
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Kansas City, KA
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
New Brunswick, NJ
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
New York, NY
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
New York, NY
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
New York, NY
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Charlotte, NC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Durham, NC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Columbus, OH
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Nashville, TN
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Houston, TX
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Seattle, WA
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
mi
from
Herston,
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
mi
from
Herston,
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
mi
from
Washington, D.C.,
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated:  9/27/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study
Status: Enrolling
Updated: 9/27/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
San Jose, CA
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
San Jose, CA
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Loxahatchee Groves, FL
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Loxahatchee Groves, FL
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Melbourne, FL
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Melbourne, FL
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Panama City, FL
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Panama City, FL
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Tallahassee, FL
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Tallahassee, FL
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Tampa, FL
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Atlanta, GA
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Louisville, KY
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Springfield, MO
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Springfield, MO
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Newark, NJ
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Newark, NJ
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Buffalo, NY
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Rochester, NY
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Greenville, NC
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Greenville, NC
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Raleigh, NC
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Portland, OR
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Germantown, TN
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Germantown, TN
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Nashville, TN
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Fort Worth, TX
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Seattle, WA
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated:  9/27/2017
GSK Investigational Site
mi
from
Madison, WI
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Evaluation of Lamotrigine in Subjects With Absence Seizures
Status: Enrolling
Updated: 9/27/2017
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials